Tips for drafting claims post-Alice

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Tips for drafting claims post-Alice

Presenters in a patent prosecution session at the AIPLA Annual Meeting shared advice and strategies for drafting claims in light of Alice v CLS Bank

Scott Pojunas from Hewlett-Packard outlined tips for preparation and prosecution of patents post-Alice.

One was to recite technical elements, including focusing your claims on a technical solution to a technical problem, and tying the claims to physical and tangible subject matter, particularly any novel hardware elements. He said a useful test is to strike through computer implementation in the claims – if the claim still makes sense, it may fail the test under 101.

A second tip was to incorporate fallback positions. This includes varying the extent to which the independent claims are tied to specific technical implementations or use cases, and using dependent claims to capture specific technological improvements.

“Are software patents dead?” asked Pojunus. “In my view, the answer is a clear no. I do think the lower courts and the PTO have an extremely difficult task ahead of them in drawing the lines that the Alice court declined to draw. And I think it will be a bumpy road for us as practitioners as the courts and Patent Office struggle with these questions. Ultimately, I think the Supreme Court will need to confront the difficult questions that it declined to answer in Alice.”

Accenture’s Matthew Weinstein noted a perception that software patents are doomed. “The mainstream media would have us all believe that any software specialized patent attorney should pack up and move on. I certainly don’t agree. There is a pretty wide spectrum [around 101]. You just have to know what that spectrum looks like, how to identify where you are on that spectrum, how to appreciate the likelihood of success, how to advise your client and how to draft specifications in these cases,” he said.

He said there is a lot to learn from the initial batch of post-Alice cases. There have been three Federal Circuit decisions, all of which have held the asserted claims unpatentable, and more than 10 district court decisions, only two of which supported the patentability of claims under 101.

“Where are we now? We still don’t have any bright line tests,” said Weinstein. “We are still out in the dark and we have to look at these cases that come down from the Federal Circuit and district courts.” He said the Ultramercial case at the Federal Circuit is probably the most important one to watch now.

He concluded with some post-Alice drafting strategies. These included: organize specifications to emphasize technical operation of specific aspects of hardware arrangements; discuss technical benefits, specifically how the claimed invention makes the system more efficient, more secure and so on; consider including emphasis on why the invention cannot be performed by a human with pen and paper; consider describing incorporated abstract ideas to set the stage for why the claims include “something more;” avoid summarizing the invention at too high a level; and avoid discussion of non-technical benefits such as economic benefits.

more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
Palińska is the business & IP law lead at CD Projekt Red in Poland
Schwitulla is the head of litigation management at Nokia in Germany
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article